EUVIMEDEUVIMED entdecken
Crossref

Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma

Nobuki Furubayashi, Jiro Tsujita, Azusa Takayama, Yuta Shiraishi, Motonobu Nakamura, Takahito Negishi

Anticancer Research · 2026

DOI: 10.21873/anticanres.18144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Nobuki Furubayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan nobumduro@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Nivolumab, Kidney Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellIpilimumabNivolumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorHumansFemaleMaleAgedMiddle AgedRetrospective StudiesDisease ProgressionAnilidesProgression-Free SurvivalPyridinesAged, 80 and over

Stichwörter der Autor:innen

Advanced renal cell carcinomacabozantinibearly progressive diseaseipilimumabnivolumabsequencing

Substanzen

IpilimumabNivolumabProtein Kinase InhibitorscabozantinibReceptors, Vascular Endothelial Growth FactorAnilidesPyridines

Autor:innen und Institutionen

  • Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan nobumduro@gmail.com.
  • Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.

Zitieren

APA

Furubayashi, N., Tsujita, J., Takayama, A., Shiraishi, Y., Nakamura, M., & Negishi, T. (2026). Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18144

Vancouver

Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T. Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18144

BibTeX
@article{Furubayashi2026,
  author = {Furubayashi, Nobuki and Tsujita, Jiro and Takayama, Azusa and Shiraishi, Yuta and Nakamura, Motonobu and Negishi, Takahito},
  title = {Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18144}
}
Kostenlos starten →